CoChat

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Open access
Thompson, George R, Soriano, Alex, Cornely, Oliver A, Kullberg, Bart Jan, Kollef, Marin, Vazquez, Jose, Honore, Patrick M, Bassetti, Matteo, Pullman, John, Chayakulkeeree, Methee, Poromanski, Ivan, Dignani, Cecilia, Das, Anita F, Sandison, Taylor, Pappas, Peter G, Akova, Murat, AlAgha, Rawan, Alangaden, George, Albrecht, Svenja J, Alexander, Barbara, Al-Obaidi, Mohanad, Ambasch, German, Armestar Rodriguez, Fernando, Azap, Alpay, Baffoe-Bonnie, Anthony, Belkhir, Leila, Ben-Ami, Ronen, Boutoille, David, Cascio, Antonio, Chai, Louis YA, Chaiwarith, Romanee, Chayakulkeeree, Methee, Chen, Sharon, Chen, Yee-Chun, Chen, Yen-Hsu, Choi, Jun Yong, Choi, Young Hwa, Chotiprasitsakul, Darunee, Chung, Jin Won, Danion, François, Denis, Blandine, Diaz Santos, Emilio, Dictar, Miguel O, Diltoer, Marc, Dupont, Herve, Feng, Sizhou, Ferre Colomer, Maria Angeles, Ferrer, Ricard, Forel, Jean-Marie Fernand Roger, Fortún-Abete, Jesús, Garcia-Diaz, Julia, Girardis, Massimo, He, Fang, Hites, Maya, Ho, Mao-Wang, Honore, Patrick, Horcajada Gallego, Juan Pablo, Huang, Haihui, Huang, Po-Yen, Huang, Yong, Hussein, Osamah, Intalapaporn, Poj, Jaruratanasirikul, Sutep, Jauregui-Peredo, Luis, Johnson, Misty, Jung, Dong Sik, Jutivorakool, Kamonwan, Kern, Winfried V, Kett, Daniel H, Khawcharoenporn, Thana, Kim, Young Keun, Koehler, Philipp, Kotanidou, Anastasia, Lachiewicz, Anne, Lin, Qinhan, Lopez Cortes, Luis Eduardo, Luo, Hong, Luzzati, Roberto, Maor, Yasmin, McCarty, Todd, Merelli, Maria, Merino Amador, Paloma, Midturi, John, Migliorino, Guglielmo Marco, Mira, Jean-Paul, Mootsikapun, Piroon, Morrissey, Orla, Munoz Garcia de Paredes, Patricia, Mussini, Cristina, Mylonakis, Eleftherios, Nseir, Saadalla, Nseir, William, Odabasi, Zekaver, Papastamopoulos, Vasileios, Paterson, David, Patterson, Thomas F, Peck, Kyong Ran, Peng, Zhiyong, Permpalung, Nitipong, Plantefeve, Gaetan J, Poromanski, Ivan G, Powell, Debra, Psichogiou, Mina, Puah, Ser Hon, Pullman, John, Rahav, Galia, Martinez, Antonio Ramos, Ramos Ramos, Juan Carlos, Raz-Pasteur, Ayelet, Restrepo Castro, Carlos A, Riera, Fernando, Roblot, France, Rodriguez Alvarez, Regino Jose, Rogers, Benjamin, Roilides, Emmanuel, Sanchez Vallejo, Gregorio, Sganga, Gabriele, Sipsas, Nikolaos, Slavin, Monica, Soriano, Alex, Spec, Andrej, Strahilevitz, Jacob, Tancheva, Dora M, Tao, Zhen, Teschner, Daniel, Thompson, George R, Van Wijngaerden, Eric, Vazquez, Jose, Vergidis, Paschalis, Viale, Pierluigi, Wang, Fu-Der, Wang, Shifu, Weber, Gabriel, Weng, Jianyu, Xu, Jinfu, Yao, Li, Yavuz, Serap, Yilmaz, Mesut, Young, Jo-Anne, Zarate, Abel H, Zeng, Jun, Zhang, Yong · 2023 · The Lancet

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index; 4 of the 21 sources its claims cite were checked for support.

Abstract

Background Rezafungin is a next-generation, once-a-week echinocandin in development for the treatment of candidaemia and invasive candidiasis and for the prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp after blood and marrow transplantation. We aimed to compare the efficacy and safety of intravenous rezafungin versus intravenous caspofungin in patients with candidaemia and invasive candidiasis.Methods ReSTORE was a multicentre, double-blind, double-dummy, randomised phase 3 trial done at 66 tertiary care centres in 15 countries. Adults (≥18 years) with systemic signs and mycological confirmation of candidaemia or invasive candidiasis were eligible for inclusion and randomly assigned (1:1) to receive intravenous rezafungin once a week (400 mg in week 1, followed by 200 mg weekly, for a total of two to four doses) or intravenous caspofungin (70 mg loading dose on day 1, followed by 50 mg daily) for no more than 4 weeks. The primary endpoints were global cure (consisting of clinical cure, radiological cure, and mycological eradication) at day 14 for the European Medical Agency (EMA) and 30-day all-cause mortality for the US Food and Drug Administration (FDA), both with a target non-inferiority margin of 20%, assessed in the modified intention-to-treat population (all patients who received one or more doses of study drug and had documented Candida infection based on a culture from blood or another normally sterile site obtained within 96 h before randomisation). Safety was evaluated by the incidence and type of adverse events and deaths in the safety population, defined as all patients who received any amount of study drug. The trial is registered with ClinicalTrials.gov, NCT03667690, and is complete.Findings Between Oct 12, 2018, and Aug 29, 2021, 222 patients were screened for inclusion, and 199 patients (118 [59%] men; 81 [41%] women; mean age 61 years [SD 15·2]) were randomly assigned (100 [50%] patients to the rezafungin group and 99 [50%] patients to the caspofungin group). 55 (59%) of 93 patients in the rezafungin group and 57 (61%) of 94 patients in the caspofungin group had a global cure at day 14 (weighted treatment difference -1·1% [95% CI -14·9 to 12·7]; EMA primary endpoint). 22 (24%) of 93 patients in the rezafungin group and 20 (21%) of 94 patients in the caspofungin group died or had an unknown survival status at day 30 (treatment difference 2·4% [95% CI -9·7 to 14·4]; FDA primary endpoint). In the safety analysis, 89 (91%) of 98 patients in the rezafungin group and 83 (85%) of 98 patients in the caspofungin group had at least one treatment-emergent adverse event. The most common treatment-emergent adverse events that occurred in at least 5% of patients in either group were pyrexia, hypokalaemia, pneumonia, septic shock, and anaemia. 55 (56%) patients in the rezafungin group and 52 (53%) patients in the caspofungin group had serious adverse events.Interpretation Our data show that rezafungin was non-inferior to caspofungin for the primary endpoints of day-14 global cure (EMA) and 30-day all-cause mortality (FDA). Efficacy in the initial days of treatment warrants evaluation. There were no concerning trends in treatment-emergent or serious adverse events. These phase 3 results show the efficacy and safety of rezafungin and support its ongoing development.Funding Cidara Therapeutics and Mundipharma.

Overview

CoChat Summary

TL;DR

In the phase 3 ReSTORE trial, once-weekly rezafungin was non-inferior to daily caspofungin for treating candidaemia and invasive candidiasis on both the EMA day-14 global cure and FDA 30-day all-cause mortality endpoints. Safety profiles were similar between groups.

Key findings

  • In the modified intention-to-treat population, day-14 global cure occurred in 55/93 (59%) rezafungin patients vs 57/94 (61%) caspofungin patients; weighted treatment difference −1·1% (95% CI −14·9 to 12·7), with the lower CI bound above the −20% non-inferiority margin.
  • 30-day all-cause mortality was 22/93 (24%) with rezafungin vs 20/94 (21%) with caspofungin; treatment difference 2·4% (95% CI −9·7 to 14·4), with the upper CI bound below the 20% non-inferiority margin.
  • Treatment-emergent adverse events occurred in 89/98 (91%) rezafungin patients vs 83/98 (85%) caspofungin patients; serious adverse events occurred in 55/98 (56%) vs 52/98 (53%), and drug-related adverse events in 16% vs 9%.
  • Exploratory early outcomes showed negative blood cultures at 24 h in 36/67 (54%) rezafungin vs 30/65 (46%) caspofungin patients and at 48 h in 49/66 (74%) vs 41/64 (64%); median time to negative blood culture was 23·9 h vs 27·0 h (p=0·18).

Methods

  • Multicentre, double-blind, double-dummy, randomised phase 3 non-inferiority trial at 66 tertiary care centres in 15 countries; adults aged ≥18 years with systemic signs and mycological confirmation of candidaemia or invasive candidiasis were randomised 1:1, with 199 patients assigned (100 rezafungin, 99 caspofungin).
  • Rezafungin was given intravenously once weekly (400 mg in week 1, then 200 mg weekly, for two to four doses); caspofungin was given intravenously (70 mg loading dose on day 1, then 50 mg daily) for no more than 4 weeks, with optional oral step-down fluconazole in the caspofungin group and matching placebo in the rezafungin group.
  • Primary endpoints were EMA-mandated day-14 global cure and FDA-mandated 30-day all-cause mortality, both with a 20% non-inferiority margin and assessed in the modified intention-to-treat population; safety was assessed in the safety population, with Miettinen-Nurminen CIs and SAS analyses.

Limitations

  • The paper states that paediatric patients and patients with certain forms of candidiasis were excluded, including forms requiring long antifungal courses (e.g., biofilm-related invasive candidiasis) or occurring at sites with poor echinocandin penetration (e.g., urinary tract and CNS); safety was also not studied in severe hepatic impairment because of the caspofungin contraindication.
  • Evident from the text: the trial was designed as a non-inferiority study, so it cannot establish superiority of rezafungin over caspofungin; subgroup and exploratory analyses, including early efficacy outcomes, were not the primary basis for inference.
  • Evident from the text: the trial enrolled a specific adult population with mostly candidaemia and excluded several complicated forms of invasive candidiasis, so generalisability to those excluded populations is limited.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)02324-8

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

2 Valid · 0 Not valid · 9 Not checked · 50 Own results and interpretations

20 more claims

Create a free account to see all 61 claims and to verify the 17 references still open.

See all claims — free account
  • It may state two separate claims as one. 26
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. Adeel, 2021, Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: a case report, Open Forum Infect Dis, 8

Cited by

See all 192

Metadata

Authors
Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., Poromanski, I., Dignani, C., Das, A. F., Sandison, T., Pappas, P. G., Akova, M., AlAgha, R., Alangaden, G., Albrecht, S. J., Alexander, B., Al-Obaidi, M., Ambasch, G., Armestar Rodriguez, F., Azap, A., Baffoe-Bonnie, A., Belkhir, L., Ben-Ami, R., Boutoille, D., Cascio, A., Chai, L. Y., Chaiwarith, R., Chayakulkeeree, M., Chen, S., Chen, Y.-C., Chen, Y.-H., Choi, J. Y., Choi, Y. H., Chotiprasitsakul, D., Chung, J. W., Danion, F., Denis, B., Diaz Santos, E., Dictar, M. O., Diltoer, M., Dupont, H., Feng, S., Ferre Colomer, M. A., Ferrer, R., Forel, J.-M. F. R., Fortún-Abete, J., Garcia-Diaz, J., Girardis, M., He, F., Hites, M., Ho, M.-W., Honore, P., Horcajada Gallego, J. P., Huang, H., Huang, P.-Y., Huang, Y., Hussein, O., Intalapaporn, P., Jaruratanasirikul, S., Jauregui-Peredo, L., Johnson, M., Jung, D. S., Jutivorakool, K., Kern, W. V., Kett, D. H., Khawcharoenporn, T., Kim, Y. K., Koehler, P., Kotanidou, A., Lachiewicz, A., Lin, Q., Lopez Cortes, L. E., Luo, H., Luzzati, R., Maor, Y., McCarty, T., Merelli, M., Merino Amador, P., Midturi, J., Migliorino, G. M., Mira, J.-P., Mootsikapun, P., Morrissey, O., Munoz Garcia de Paredes, P., Mussini, C., Mylonakis, E., Nseir, S., Nseir, W., Odabasi, Z., Papastamopoulos, V., Paterson, D., Patterson, T. F., Peck, K. R., Peng, Z., Permpalung, N., Plantefeve, G. J., Poromanski, I. G., Powell, D., Psichogiou, M., Puah, S. H., Pullman, J., Rahav, G., Martinez, A. R., Ramos Ramos, J. C., Raz-Pasteur, A., Restrepo Castro, C. A., Riera, F., Roblot, F., Rodriguez Alvarez, R. J., Rogers, B., Roilides, E., Sanchez Vallejo, G., Sganga, G., Sipsas, N., Slavin, M., Soriano, A., Spec, A., Strahilevitz, J., Tancheva, D. M., Tao, Z., Teschner, D., Thompson, G. R., Van Wijngaerden, E., Vazquez, J., Vergidis, P., Viale, P., Wang, F.-D., Wang, S., Weber, G., Weng, J., Xu, J., Yao, L., Yavuz, S., Yilmaz, M., Young, J.-A., Zarate, A. H., Zeng, J., & Zhang, Y.
Affiliations
  • University of Cologne (DE)
  • Radboud University Medical Center (NL)
  • Washington University in St. Louis (US)
  • Ospedale Policlinico San Martino (IT)
  • Cidara Therapeutics (United States) (US)
  • University of Alabama at Birmingham (US)
  • University of California Davis Medical Center (US)
  • Siriraj Hospital (TH)
  • Université Libre de Bruxelles (BE)
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-01
Volume
401
Issue
10370
Pages
49-59
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4309967380
Cited by
192
References
28
Citations by year
2026: 47 · 2025: 54 · 2024: 59 · 2023: 30
FWCI
17.57
Type
journal article
Language
en
Open access
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by-nc-nd)
  • National University of Singapore (submittedVersion)
  • Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
  • Digital Access to Libraries (submittedVersion, other-oa)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • Dspace Repository (Marmara Üniversitesi) (submittedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
Cidara Therapeutics
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords
caspofungin, candidemia, invasive candidiasis, echinocandins, antifungal therapy, non-inferiority, 30-day mortality, adverse events, fungal infection treatment, double-dummy design, RESTORE trial, Candida
MeSH terms
Caspofungin, Adult, Candidiasis, Double-Blind Method, Female, Humans, Male, Middle Aged, Treatment Outcome, Echinocandins, Candidiasis, Invasive, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)02324-8
The paper
Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., Poromanski, I., Dignani, C., Das, A. F., Sandison, T., Pappas, P. G., Akova, M., AlAgha, R., Alangaden, G., Albrecht, S. J., . . . Zhang, Y. (2023). Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)02324-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.